Current schizophrenia drugs: Efficacy and side effects

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 8, 2006, Pages 1005-1016

  Krebs, Michael ^a   Leopold, Karolina ^a   Hinzpeter, Axel ^a   Schaefer, Martin ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Antipsychotics; Atypical; Efficacy; Safety; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; INSULIN; NEUROLEPTIC AGENT; NICOTINIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PLACEBO; PROLACTIN; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIACYLGLYCEROL; ZIPRASIDONE; ZOTEPINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGRANULOCYTOSIS; AKATHISIA; AMENORRHEA; BODY WEIGHT DISORDER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE MANAGEMENT; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPHORIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE SEXUAL DYSFUNCTION; GALACTORRHEA; GLUCOSE INTOLERANCE; GYNECOMASTIA; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INFERTILITY; INSULIN BLOOD LEVEL; LEUKOPENIA; LONG TERM CARE; MALE SEXUAL DYSFUNCTION; META ANALYSIS; METABOLIC DISORDER; MYOCARDITIS; NEGATIVE SYNDROME; OLIGOMENORRHEA; PARKINSONISM; PATIENT COMPLIANCE; PERICARDITIS; PHARMACOGENETICS; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QUALITY OF LIFE; RECEPTOR AFFINITY; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TORSADE DES POINTES; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COGNITION; HUMANS; LONG QT SYNDROME; PATIENT COMPLIANCE; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 33745473335     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.8.1005     Document Type: Review

References (100)

1. FALKAI P, WOBROCK T, LIEBERMAN J et al: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry (2005) 6(3):132-191.
2. MOLLER HJ: Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs (2003) 17(11):793-823.
3. HIPPIUS H: A historical perspective of clozapine. J. Clin. Psychiatry (1999) 60(Suppl. 12):22-23.
4. MIYAMOTO S, DUNCAN GE, MARX CE, LIEBERMAN JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry (2005) 10(1):79-104.
5. KANE JM, LEUCHT S, CARPENTER D, DOCHERTY JP: Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry (2003) 64(Suppl. 12):5-19.
6. STAHL SM: 'Hit-and-run' actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. J. Clin. Psychiatry (2001) 62(9):670-671.
7. MELTZER HY, MCGURK SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. (1999) 25(2):233-255.
8. KROEZE WK, HUFEISEN SJ, POPADAK BA et al.: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 28(3):519-526.
9. KAPUR S, SEEMAN P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry (2001) 158(3):360-369.
10. GLAZER WM: Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J. Clin. Psychiatry (2000) 61(Suppl. 3):16-21.
11. CASEY DE: Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry (2004) 65(Suppl. 9):25-28.
12. JOY CB, ADAMS CE, LAWRIE SM: Haloperidol versus placebo for schizophrenia. Cochrane. Database. Syst. Rev. (2001) 2:CDO03082.
13. ADAMS CE, RATHBONE J, THORNLEY B et al.: Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Med. (2005) 3(1):15.
14. MELTZER HY, THOMPSON PA, LEE MA, RANJAN R: Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology (1996) 14(3 Suppl.):27S-33S.
15. CORRELL CU, LEUCHT S, KANE JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry (2004) 161(3):414-425.
16. DAVIS JM, CHEN N: Dose response and dose equivalence of antipsychotics. J Clin. Pychopharmacol. (2004) 24(2):192-208.
17. GEDDES J, FREEMANTLE N, HARRISON P, BEBBINGTON P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. (2000) 321(7273):1371-1376.
18. LEUCHT S, PITSCBEL-WALZ G, ABRAHAM D, KISSLING W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. (1999) 35(1):51-68.
19. DAVIS JM, CHEN N, GLICK ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry (2003) 60(6):553-564.
20. LIEBERMAN JA, STROUP TS, MCEVOY JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. (2005) 353(12):1209-1223.
21. DAVIS JM, CHEN N: Choice of maintenance medication for schizophrenia. J. Clin. Psychiatry (2003) 64(Suppl. 16):24-33.
22. GUMLEY A, O'GRADY M, MCNAY L et al.: Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. Psychol. Med. (2003) 33(3):419-431.
23. SCHOOLER NR: Relapse and rehospitalization: comparing oral and depot antipsychotics. J. Clin. Psychiatry (2003) 64(Suppl. 16):14-17.
24. GAEBEL W, PIETZCKER A: Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment. Eur. Arch. Psychiatry Neurol. Sci. (1985) 235(1):45-52.
25. BEASLEY CM, JR., SUTTON VK, HAMILTON SH et al.: A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J. Clin. Psychopharmacol. (2003) 23(6):582-594.
26. SCHOOLER N, RABINOWITZ J, DAVIDSON M et al.: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry (2005) 162(5):947-953.
27. LEUCHT S, BARNES TR, KISSLING W et al.: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry (2003) 160(7):1209-1222.
28. DOSSENBACH M, ARANGO-DAVILA C, SILVA IH et al.: Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J. Clin. Psychiatry (2005) 66(8):1021-1030.
29. MOLLER HJ, MULLER H, BORISON RL, SCHOOLER NR, CHOUINARD G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. (1995) 245(1):45-49.
30. TOLLEFSON GD, SANGER TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry (1997) 154(4):466-474.
31. MCKEAGE K, PLOSKER GL: Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs (2004) 18(13):933-956.
32. HARVEY PD, KOREN D, REICHENBERG A, BOWIE CR: Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr. Bull. (2006) 32(2):250-258.
33. KEEFE RS, SILVA SG, PERKINS DO, LIEBERMAN JA: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. (1999) 25(2):201-222.
34. GOLDBERG TE, WEINBERGER DR: Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J. Clin. Psychiatry (1996) 57(Suppl. 9):62-65.
35. MISHARA AL, GOLDBERG TE: A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psychiatry (2004) 55(10):1013-1022.
36. BILDER RM, GOLDMAN RS, VOLAVKA J et al.: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry (2002) 159(6):1018-1028.
37. PURDON SE, JONES BD, STIP E et al.: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch. Gen. Psychiatry (2000) 57(3):249-258.
38. GREEN MF, MARDER SR, GLYNN SM et al.: The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry (2002) 51(12):972-978.
39. KEEFE RS, YOUNG CA, ROCK SL et al.: One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. (2006) 81(1):1-15.
40. HARVEY PD, MELTZER H, SIMPSON GM et al.: Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr. Res. (2004) 66(2-3):101-113.
41. WAGNER M, QUEDNOW BB, WESTHEIDE J et al.: Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine versus amisulpride. Neuropsychopharmacology (2005) 30(2):381-390.
42. KOPALA LC, GOOD KP, MILLIKEN H et al.: Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr Res. (2006) 81(1):29-39.
43. CONLEY RR, KELLY DL: Management of treatment resistance in schizophrenia. Biol. Psychiatry (2001) 50(11):898-911.
44. ZIEGENBEIN M, SIEBERER M, CALLIESS IT, KROPP S: Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust. N. Z. J. Psychiatry (2005) 39(9):840-841.
45. ZINK M, KNOPF U, HENN FA, THOME J: Combination of clozapine and amisulpride in treatment-resistant schizophrenia-case reports and review of the literature. Pharmacopsychiatry (2004) 37(1):26-31.
46. CHAKOS M, LIEBERMAN J, HOFFMAN E, BRADFORD D, SHEITMAN B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry (2001) 158(4):518-526.
47. KANE JM, KHANNA S, RAJADHYAKSHA S, GILLER E: Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol (2006) 21(1):21-28.
48. PERKINS DO: Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry (2002) 63(12):1121-1128.
49. DOLDER CR, LACRO JP, DUNN LB, JESTE DV: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am. J. Psychiatry (2002) 159(1):103-108.
50. KAROW A, NABER D: Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (2002) 162(1):3-10.
51. NABER D, KAROW A, LAMBERT M: Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr. Scand. Suppl. (2005) 427:29-34.
52. LAMBERT M, NABER D: Current issues in schizophrenia: overview of patient acceptability, functioning rapacity and quality of life. CNS Drugs (2004) 18(Suppl.):25-17.
53. AWAD AG, VORUGANTI LN: New antipsychotics, compliance, quality of life, and subjective tolerability-are patients better off? Can. J. Psychiatry (2004) 49(5):297-302.
54. REMINGTON G: Understanding antipsychotic 'atypicality': a clinical and pharmacological moving target. J. Psychiatry Neurosci. (2003) 28(4):275-284.
55. BARNES TR, MCPHILLIPS MA: Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int. Clin. Psychopharmacol. (1998) 13(Suppl. 3):S49-S57.
56. TOLLEFSON GD, BEASLEY CM Jr, TAMURA RN, TRAN PV, POTVIN JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry (1997) 154(9):1248-1254.
57. SMALL JG, HIRSCH SR, ARVANITIS LA, MILLER BG, LINK CG: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry (1997) 54(6):549-557.
58. GUNASEKARA NS, SPENCER CM, KEATING GM: Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs (2002) 62(8):1217-1251.
59. JAUSS M, SCHRODER J, PANTEL J et al.: Severe akathisia during olanzapine treatment of acute schizophrenia. Pharmacopsychiatry (1998) 31(4):146-148.
60. KECK PE Jr, VERSIANI M, POTKIN S et al.: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry (2003) 160(4):741-748.
61. RIEDEL M, SCHWARZ MJ, STRASSNIG M et al.: Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. (2005) 255(4):261-268.
62. BRESSAN RA, JONES HM, PILOWSKY LS: Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. J. Psychopharmacol. (2004) 18(1):124-127.
63. ALLISON DB, MENTORE JL, HEO M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156(11):1686-1696.
64. WETTERLING T: Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. (2001) 24(1):59-73.
65. ROSENBERG DE, JABBOUR A, GOLDSTEIN BJ: Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes Obes. Metah. (2005) 7(6):642-653.
66. AMERICAN DIABETES ASSOCIATION: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 27(2):596-601.
67. CASEY DE: Dyslipidemia and atypical antipsychotic drugs. J. Clin. Psychiatry (2004) 65(Suppl. 18):27-35.
68. BOBES J, REJAS J, GARCIA-GARCIA M et al.: Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr. Res. (2003) 62(1-2):77-88.
69. JAYARAM MB, HOSALLI P: Risperidone versus olanzapine for schizophrenia. Cochrane. Database. Syst. Rev. (2005) 2:CDO05237.
70. RAK IW, JONES AM, RANIWALLA J, PHUNG D, MELVIN K: Weight changes in patients treated with Seroquel (quetiapine). Schizophr. Res. (2000) 41:206 (Abstr. B.83).
71. LEUCHT S, WAGENPFEIL S, HAMANN J, KISSLING W: Amisulpride is an 'atypical' antipsychotic associated with low weight gain. Psychopharmacology (2004) 173(1-2):112-115.
72. MCQUADE RD, STOCK E, MARCUS R et al.: A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry (2004) 65(Suppl. 18):47-56.
73. BREIER A, BERG PH, THAKORE JH et al.: Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am. J. Psychiatry (2005) 162(10):1879-1887.
74. BAPTISTA T, ZARATE J, JOOBER R et al.: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr. Drug Targets. (2004) 5(3):279-299.
75. KINON BJ, KAISER CJ, AHMED S, ROTELLI MD, KOLLACK-WALKER S: Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J. Clin. Psychopharmacol. (2005) 25(3):255-258.
76. GRAHAM KA, PERKINS DO, EDWARDS LJ et al.: Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am. J. Psychiatry (2005) 162(1):118-123.
77. TSAI SJ, HONG CJ, YU YW, LIN CH: -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet (2002) 360(9347):1790.
78. BUCKLAND PR, HOOGENDOORN B, GUY CA et al.: Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am. J. Psychiatry (2005) 162(3):613-615.
79. MEYER JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry (2002) 63(5):425-433.
80. FARWELL WR, STUMP TE, WANG J et al.: Weight gain and new onset diabetes associated with olanzapine and risperidone. J. Gen. Intern. Med. (2004) 19(12):1200-1205.
81. MEYER JM: Novel antipsychotics and severe hyperlipidemia. J. Clin. Psychpharmacol. (2001) 21(4):369-374.
82. MEYER JM, KORO CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. (2004) 70(1):1-17.
83. AIZENBERG D, MODAI I, LANDA A, GIL-AD I, WEIZMAN A: Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J. Clin. Psychiatry (2001) 62(7):541-544.
84. HADDAD PM, WIECK A: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs (2004) 64(20):2291-2314.
85. KELLY DL, CONLEY RR: Sexuality and schizophrenia: a review. Schizophr. Buff (2004) 30(4):767-779.
86. KIM KS, PAE CU, CHAE JH et al.: Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J. Clin. Psychiatry (2002) 63(5):408-413.
87. STOLLBERGER C, HUBER JO, FINSTERER J: Antipsychotic drugs and QT prolongation. Int. Clin. Psychopharmacol. (2005) 20(5):243-251.
88. HADDAD PM, ANDERSON IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs (2002) 62(11):1649-1671.
89. GLASSMAN AH, BIGGER JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry (2001) 158(11):1774-1782.
90. WEHMEIER PM, HEISER P, REMSCHMIDT H: Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J. Clin. Pharm. Ther. (2005) 30(1):91-96.
91. MERRILL DB, DEC GW. GOFF DC: Adverse cardiac effects associated with clozapine. J. Clin. Psychopharmacol. (2005) 25(1):32-41.
92. BRAKOULIAS V, BANNAN E, COHEN P, GEARY G: Amisulpride and cardiomyopathy. Aust. N. Z. J. Psychiatry (2005) 39(8):738.
93. ROESCH-ELY D, VAN EINSIEDEL R, KATHOFER S, SCHWANINGER M, WEISBROD M: Myocarditis with quetiapine. Am. J. Psychiatry (2002) 159(9):1607-1608.
94. COULTER DM, BATE A, MEYBOOM RH, LINDQUIST M, EDWARDS IR: Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. Br. Med. J. (2001) 322(7296):1207-1209.
95. MILLER DD: Review and management of clozapine side effects. J. Clin. Psychiatry (2000) 61(Suppl. 8):14-17.
96. ALVIR JM, LIEBERMAN JA, SAFFERMAN AZ, SCHWIMMER JL, SCHAAF JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. (1993) 329(3):162-167.
97. STUBNER S, GROHMANN R, ENGEL R et al.: Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry (2004) 37(Suppl. 1):S70-S78.
98. RUHE HG, BECKER HE, JESSURUN P et al.: Agranulocytosis and granulocytopenia associated with quetiapine. Acta Psychiatr. Scand. (2001) 104(4):311-313.
99. TOLOSA-VILELLA C, RUIZ-RIPOLL A, MARI-ALFONSO B, NAVAL-SENDRA E: Olanzapine-induced agranulocytosis: a case report and review of the literature. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26(2):411-414.
100. HERES S, DAVIS J, MAINO K et al.: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry (2006) 163(2):185-194.